Development of Fast-Dissolving Tablets of Flurbiprofen-Cyclodextrin Complexes

References

• Banker, G. S., & Anderson, N. R. (1986). Tablets. In: L. Lachman, H. A. Lieberman, & J. L. Kanig (Eds.), The Theory and Practice of Industrial Pharmacy. Philadelphia: Lea and Febiger.
   Google Scholar
• Bettinetti, G. P., Gazzaniga, A., Mura, P., Giordano, F., & Setti, M. (1992). Thermal behaviour and dissolution properties of naproxen in combinations with chemically modified β-cyclodextrins. Drug Development and Industrial Pharmacy, 18, 39–53., [CSA]
   Web of Science ®Google Scholar
• Chow, D. D., & Karara, A. H. (1986). Characterization, dissolution and bioavailability in rats of ibuprofen-β-cyclodextrin complex system. International Journal of Pharmaceutics, 28, 95–101., [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Corrigan, O. I., & Stanley, T. (1982). Mechanism of drug dissolution rate enhancement from β-cyclodextrin-drug systems. Journal of Pharmacy and Pharmacology, 34, 621–626., [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Dressman, J., Butler, J., Hempenstall, J., & Reppas, C. (2001). The Biopharmaceutics Classification System (BCS): where do we go from here? Pharmaceutical Technology North America, 25, 68–76., [CSA]
   Google Scholar
• (2002). European Pharmacopeia (4th ed.). StrasbourgFrance: Council of Europe.
   Google Scholar
• Green, A. R., & Guillory, J. K. (1989). Heptakis(2,6-di-O-methyl)-β-cyclodextrin complexation with antitumor agent chlorambucil. Journal of Pharmaceutical Sciences, 78, 427–431., [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Imai, T., Otagiri, M., Saito, H., & Uekama, K. (1988). Inclusion mode of flurbiprofen with β-cyclodextrin and heptakis(2,3,6-tri-O-methyl)-β-cyclodextrin, and improvements of some pharmaceutical properties of flurbiprofen by complexation. Chemical and Pharmaceutical Bulletin, 36, 354–359., [CSA]
   PubMed Web of Science ®Google Scholar
• Khan, K. A. (1975). The concept of dissolution efficiency. Journal of Pharmacy and Pharmacology, 27, 48–49., [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kim, K. H., Frank, M. J., & Henderson, N. L. (1985). Applications of differential scanning calorimetry to the study of solid drug dispersions. Journal of Pharmaceutical Sciences, 74, 283–289., [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Knapczzyk, K. (1993). Excipients ability of chitosan for direct tableting. International Journal of Pharmaceutics, 89, 1–7., [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Kusuhara, H., Komatsu, H., Sumichika, H., & Sugahara, K. (1999). Reactive oxygen species are involved in the apoptosis induces by nonsteroidal anti-inflammatory drugs in cultured gastric cells. European Journal of Pharmacology, 383, 331–337., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Loftsson, T. (2002). Cyclodextrins and the biopharmaceutics classification system of drugs. Journal of Inclusion Phenomena, 44, 63–67., [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Mura, P., Bettinetti, G. P., Melani, F., & Manderioli, A. (1995). Interaction between naproxen and chemically-modified β-cyclodextrins in the liquid and solid state. European Journal of Pharmaceutical Sciences, 3, 347–355., [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Mura, P., Bettinetti, G. P., Manderioli, A., Faucci, M. T., Bramanti, G., & Sorrenti, M. (1998). Interactions of ketoprofen and ibuprofen with β-cyclodextrins in solution and in the solid state. International Journal of Pharmaceutics, 166, 189–203., [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Mura, P., Zerrouck, N., Faucci, M. T., Maestrelli, F., & Chemtob, C. (2002). Comparative study of ibuproxam complexation with amorphous β-cyclodextrin derivatives in solution and in the solid state. European Journal of Pharmaceutics and Biopharmaceutics, 54, 181–191., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Nakai, Y., Yamamoto, K., Terada, K., Horibe, H., & Ozawa, K. (1983). Interaction of tri-O-methyl-β-cyclodextrin with drugs II: enhanced bioavailability of ketoprofen in rats. Chemical and Pharmaceutical Bulletin, 31, 37–45., [CSA]
   Google Scholar
• Nakai, Y., Yamamoto, K., Terada, K., & Horibe, H. (1984). Interaction of tri-O-methyl-β-cyclodextrin with drugs. Journal of Inclusion Phenomena, 2, 523–531., [CSA], [CROSSREF]
   Google Scholar
• Nogami, H., Nagai, T., & Yotsuyanagi, I. (1969). Dissolution phenomena of organic medicinals involving simultaneous phase changes. Chemical and Pharmaceutical Bulletin, 17, 499–509., [CSA]
   Web of Science ®Google Scholar
• Otagiri, M., Imai, T., Hirayama, F., & Uekama, K. (1983a). Inclusion complex formation of the antiinflammatory drug flurbiprofen with cyclodextrins in aqueous solutions and in the solid state. Acta Pharmaceutica Suecica, 20, 11–20., [CSA]
   Google Scholar
• Otagiri, M., Imai, T., Matsuo, N., & Uekama, K. (1983b). Improvements to some pharmaceutical properties of flurbiprofen by β- and γ-cyclodextrin complexations. Acta Pharmaceutica Suecica, 20, 1–10., [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Otero-Espinar, F. J., Anguiano-Igea, S., Blanco-Mendez, J., & Vila-Jato, J. L. (1991a). Reduction in the ulcerogenicity of naproxen by complexation with β-cyclodextrin. International Journal of Pharmaceutics, 70, 35–41., [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Otero-Espinar, F. J., Anguiano-Igea, S., Garcia-Gonzalez, N., Vila-Jato, J. L., & Blanco-Mendez, J. (1991b). Oral bioavailability of naproxen-β-cyclodextrin inclusion compound. International Journal of Pharmaceutics, 75, 37–44., [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• (2001). The Biopharmaceutics Classification System (BCS) Guidance. Center for Drug Evaluation and Research, US Food and Drug Administration (FDA).
   Google Scholar